Designed for the Clinic. Built for the Patient
Immunogenik was founded to bring new hope to patients with aggressive,
difficult-to-treat tumors. Our pipeline of cell and antibody therapies are designed
to overcome the tumor defenses and radically improve patient survival
Our dedication to this vision guides every step we take
Explore Our Technology
The 8R-70 CAR design uniquely combines CD70 targeting with an IL-8 receptor to enhance tumor homing, persistence, and memory recall of CAR T cells within the tumor microenvironment, overcoming the greatest barriers to CAR T success in solid tumors.
The humanized LAIR1 antibody blocks LAIR1, a critical immune checkpoint expressed on tumor-associated myeloid cells, reprogramming the tumor microenvironment to restore immune function and enhance antitumor efficacy.
A multifunctional CAR T-cell platform engineered to overcome tumor immune resistance by integrating antigen recognition, enhanced T-cell trafficking, and intrinsic immune checkpoint blockade.